COMP: A candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker

Annals of the Rheumatic Diseases

Volumn 67, Issue 9, 2008, Pages 1242-1248

  Hesselstrand, R ^a,c   Kassner, A ^b   Heinegard D ^b   Saxne, T ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; SKIN BIOPSY; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; WESTERN BLOTTING;

BIOLOGICAL MARKERS; BIOPSY; CROSS-SECTIONAL STUDIES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXTRACELLULAR MATRIX PROTEINS; GLYCOPROTEINS; HUMANS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 50249149816     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.082099     Document Type: Article

References (38)

1. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005;26:587-95.
2. Valentini G, Bencivelli W, Bombardieri S, D'Angelo S, Della Rossa A, Silman AJ, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62:901-3.
3. Åkesson A, Wollheim FA, Thysell H, Gustafson T, Forsberg L, Pahlm O, et al. Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis. Scand J Rheumatol 1988;17:313-23.
4. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828-35.
5. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
6. Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, et al. Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo- controlledphase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33.
7. Hesselstrand R, Scheja A, Åkesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-6.
8. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979;22:130-40.
9. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-91.
10. McHugh NJ, Distler O, Giacomelli R, Riemekasten G. Non organ based laboratory markers in systemic sclerosis. Clin Exp Rheumatol 2003;21(3 Suppl 29):S32-8.
11. Scheja A, Wildt M, Wollheim FA, Åkesson A, Saxne T. Cirkulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatology 2000;39:1110-3.
12. Hedbom E, Antonsson P, Hjerpe A, Aeschlimann D, Paulsson M, Rosa-Pimentel E, et al. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992;267:6132-6.
13. Smith RK, Zunino L, Webbon PM, Heinegård D. The distribution of cartilage oligomeric matrix protein (COMP) in tendon and its variation with tendon site, age and load. Matrix Biol 1997;16:255-71.
14. DiCesare P, Hauser N, Lehman D, Pasumarti S, Paulsson M. Cartilage oligomeric matrix protein (COMP) is an abundant component of tendon. FEBS Lett 1994;354:237-40.
15. Dodge GR, Hawkins D, Boesler E, Sakai L, Jimenez SA. Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblasts. Osteoarthritis Cartilage 1998;6:435-40.
16. Rosenberg K, Olsson H, Morgelin M, Heinegård D. Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen. J Biol Chem 1998;273:20397-403.
17. Halasz K, Mörgelin M, Kassner A, Heinegård D. COMP acts as a catalyst in collagen fibrillogenesis. J Biol Chem 2007;43:31166-73.
18. Lorenzo P, Bayliss MT, Heinegård D. Altered pattern and synthesis of extracellular matrix macromolecules in early osteoarthritis. Matrix Biol 2004;23:381-91.
19. Giannoni P, Siegrist M, Hunziker EB, Wong M. The mechanosensitivity of cartilage oligomeric matrix protein (COMP). Biorheology 2003;40:101-9.
20. Petersson IF, Boegard T, Svensson B, Heinegård D, Saxne T. Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br J Rheumatol 1998;37:46-50.
21. Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999;42:2356-64.
22. Sharif M, Kirwan JR, Elson CJ, Granell R, Clarke S. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum 2004;50:2479-88.
23. Saxne T, Heinegård D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992;31:583-91.
24. Månsson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR, et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995;95:1071-7.
25. Saxne T, Månsson B, Heinegård D. Biomarkers for cartilage and bone in rheumatoid arthritis. In Firestein GS, Panayi GS, Wollheim FA, eds. Rheumatoid arthritis: new frontiers in pathogenesis and treatment. 2nd edn. Oxford, UK: Oxford University Press, 2006:301-13.
26. Gardner H, Strehlow D, Bradley L, Widom R, Farina A, de Fougerolles A, et al. Global expression analysis of the fibroblast transcriptional response to TGFβ. Clin Exp Rheumatol 2004;22(Suppl 33):S47-57.
27. Tan FK, Hildebrand BA, Lester MS, Stivers DN, Pounds S, Zhou X, et al. Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum 2005;52:865-76.
28. Farina G, Lemaire R, Korn JH, Widom RL. Cartilage oligomeric matrix protein is overexpressed by scleroderma dermal fibroblasts. Matrix Biol 2006;25:213-22.
29. Smith RKW, Zunino L, Webbon PM. Heinegård D. The distribution of cartilage digomeric matrix protein (COMP) in tendon and its variation with tendon site, age and load. Matrix Biol 1997;16:255-71.
30. Masi AT, Medsger TA, Jr., Altman RD, D'Angelo WA, Fries JF, LeRoy EC, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
31. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
32. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
33. Åkesson A, Hesselstrand R, Scheja A, Wildt M. Longitudinal development of skin involvement and reliability of high freguency ultrasound in systemic sclerosis. Ann Rheum Dis 2004;63:791-6.
34. Di Cesare PE, Chen FS, Moergelin M, Carlson CS, Leslie MP, Perris R, et al. Matrix-matrix interaction of cartilage oligomeric matrix protein and fibronectin. Matrix Biol 2002;21:461-70.
35. Vallejo AN, Yang H, Klimiuk PA, Weyand CM, Goronzy JJ. Synoviocyte-mediated expansion of inflammatory T cells in rheumatoid synovitis is dependent on CD47-thrombospondin 1 interaction. J Immunol 2003;171:1732-40.
36. Graf R, Freyberg M, Kaiser D, Friedl P. Mechanosensitive induction of apoptosis in fibroblasts is regulated by thrombospondin-1 and integrin associated protein (CD47). Apoptosis 2002;7:493-8.
37. Farina G, Widom RL, Benvenuto R, De Santis M, Tolusso B, Ferraccioli G. COMP as a marker of active fibrosis in scleroderma: Immunohistochemical analysis of skin, lung and, kidney tissue. Arthritis Rheum 2006;52(Suppl 9):S729.
38. Meyer O. Prognostic markers for systemic sclerosis. Joint Bone Spine 2006;73:490-4.